Saturday 17 October 2026
Export TOVX’s income statement to Excel — free account
Theriva Biologics, Inc.
TOVX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.4%, free cash flow grew 34.7% and total debt fell 1.16%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.00
0.00%
Follow TOVX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(166.95%) | (146.58%) | (148.69%) | (115.11%) | |
| (73.83%) | (68.62%) | (65.24%) | (37.14%) | ||
ROIC |
(1,921.88%) | (375.98%) | (79.89%) | (301.72%) | |
Return on Tangible Assets |
3,077.44% | (328.98%) | (343.49%) | (757.53%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.91) | (1.38) | (0.35) | (0.28) | |
Free Cash Flow |
(18.51) | (16.70) | (14.37) | (12.78) | |
Capital Expenditures |
(0.03) | (0.03) | — | (0.04) | |
| Other line items | |||||
Cash ROIC |
(116.29%) | (55.48%) | (84.40%) | (50.83%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.66 | 0.63 | 0.97 | |
Depreciation/Fixed assets |
0.43 | 0.49 | 0.55 | 0.60 | |
Capex/Depreciation |
(0.32) | (0.32) | 0.00 | (0.37) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.91) | (1.37) | (0.35) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates